GM-XAN005

GM-XAN005 is a preclinical-stage botanical drug candidate being developed by Xantho Biotechnology for the treatment of diabetic wounds. Developed by a company specializing in botanical new drugs with low side effects, GM-XAN005 has demonstrated efficacy in preclinical experiments involving diabetic rat models. While specific molecular targets and the exact active botanical ingredients have not been publicly disclosed, the drug is part of a pipeline focused on dermatological applications and inflammatory pathways. The company's broader research often involves the modulation of inflammatory cytokines, though the specific mechanism for GM-XAN005 remains proprietary.